Geode Capital Management
KLRS

Geode Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Geode Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
87,545
+4,898
+6% +$43.5K ﹤0.01% 3579
2025
Q4 		$698K Buy
82,647
+18,096
+28% +$116K ﹤0.01% 3480
2025
Q3 		$373K Buy
64,551
+39,075
+153% +$129K ﹤0.01% 3722
2025
Q2 		$68K Sell
25,476
-1,311
-5% -$5.92K ﹤0.01% 4155
2025
Q1 		$215K Buy
26,787
+1,362
+5% +$13.3K ﹤0.01% 3826
2024
Q4 		$246K Sell
25,425
-34
-0.1% -$514 ﹤0.01% 3837
2024
Q3 		$474K Sell
25,459
-2,692
-10% -$47.1K ﹤0.01% 3595
2024
Q2 		$468K Sell
28,151
-27,237
-49% -$481K ﹤0.01% 3582
2024
Q1 		$962K Buy
55,388
+899
+2% +$14.7K ﹤0.01% 3372
2023
Q4 		$852K Buy
54,489
+3,218
+6% +$127K ﹤0.01% 3412
2023
Q3 		$2.54M Buy
51,271
+11,123
+28% +$758K ﹤0.01% 2987
2023
Q2 		$3.14M Buy
40,148
+5,771
+17% +$549K ﹤0.01% 2944
2023
Q1 		$3.12M Buy
34,377
+1,246
+4% +$159K ﹤0.01% 2839
2022
Q4 		$3.91M Buy
33,131
+315
+1% +$53.4K ﹤0.01% 2782
2022
Q3 		$5.96M Buy
32,816
+8,857
+37% +$1.38M ﹤0.01% 2576
2022
Q2 		$2.15M Buy
23,959
+45
+0.2% +$4.72K ﹤0.01% 3087
2022
Q1 		$3.71M Buy
23,914
+516
+2% +$103K ﹤0.01% 2958
2021
Q4 		$6.96M Buy
23,398
+1,043
+5% +$484K ﹤0.01% 2694
2021
Q3 		$12.9M Buy
22,355
+3,591
+19% +$1.66M ﹤0.01% 2278
2021
Q2 		$8.52M Buy
18,764
+173
+0.9% +$89.3K ﹤0.01% 2573
2021
Q1 		$10M Buy
18,591
+5,118
+38% +$4.3M ﹤0.01% 2370
2020
Q4 		$11.9M Buy
13,473
+476
+4% +$366K ﹤0.01% 2045
2020
Q3 		$8.22M Buy
+12,997
New +$8.88M ﹤0.01% 2072

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management's KLRS Position: Q1 2026 in Review

Geode Capital Management increased its Kalaris Therapeutics (KLRS) stake by 5.9% in Q1 2026, buying an estimated $43.5K and bringing the position to 87,545 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #3579.

Geode Capital Management first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $12.9M in Q3 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Geode Capital Management held 87,545 shares of Kalaris Therapeutics worth $505K as of Q1 2026.
  • Geode Capital Management bought 4,898 Kalaris Therapeutics shares in Q1 2026, an estimated $43.5K.
  • Kalaris Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3579 holding.
  • Geode Capital Management first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Kalaris Therapeutics position peaked at $12.9M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.